A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Real-world results of first-line immunotherapy or targeted therapy for metastatic melanoma in Finland: a cohort study
Tekijät: Mattila, Kalle E; Tiainen, Leena; Vikkula, Johanna; Kreutzman, Anna; Engström-Risku, Mia; Kysenius, Kai; Hölsä, Olivia; Hernesniemi, Sari; Hemmilä, Päivikki; Pystynen, Anssi; Mäkelä, Siru
Kustantaja: Informa UK Limited
Julkaisuvuosi: 2024
Journal: Future Oncology
Tietokannassa oleva lehden nimi: Future Oncology
Lehden akronyymi: Future Oncol
Vuosikerta: 20
Numero: 40
Aloitussivu: 3491
Lopetussivu: 3505
ISSN: 1479-6694
eISSN: 1744-8301
DOI: https://doi.org/10.1080/14796694.2024.2403329
Verkko-osoite: https://doi.org/10.1080/14796694.2024.2403329
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/458351160
Aim: First-line (1L) immunotherapy has yielded superior overall survival (OS) in metastatic melanoma (MM) but some patients are ineligible for immunotherapy or need rapid response with 1L targeted therapy (TT).
Materials & methods: Retrospective cohort study of real-world patients treated with 1L immunotherapy (144 BRAF wild type, 85 BRAF-mutated) or 1L TT (143 BRAF-mutated) for MM in Finland during 2014-2021.
Results: Baseline brain metastases, liver metastases and elevated LDH were less common, 2-year OS rates were higher (60.3-63.5% vs. 33.8%) and more patients were alive without the next-line treatment (38.0-43.8% vs. 23.3%) in patients with 1L immunotherapy.
Conclusion: Real-world patients with 1L immunotherapy for MM had favorable baseline characteristics and better treatment outcomes than observed in patients with 1L TT.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
